MethylGene grows over 90%
MethylGene Inc.
(Public, TSE:MYG)
Grows over 90% on pre-clinical data that is not more promising then anything seen out of PharmaGap!
Any thought on this?
https://www.reuters.com
"
MethylGene Inc. Presents Encouraging Clinical Data For MGCD265 In Solid Tumor Cancers
Thursday, 18 Nov 2010 08:05am EST
MethylGene Inc. announced safety and efficacy clinical data for MGCD265. Data was presented for the Company's two-arm trial (Trial 103) in which MGCD265 is administered in combination with either docetaxel or erlotinib in solid tumor patients. MGCD265 is a proprietary oral multi-targeted receptor tyrosine kinase inhibitor. In the docetaxel arm of Trial 265-103 (MGCD265 in combination with full-dose docetaxel), 18 patients with advanced solid malignancies have been enrolled. MGCD265 is administered orally daily in combination with docetaxel once every 21 days (one cycle) in patients with advanced solid malignancies. Twice per day (BID) dosing of MGCD265 has been initiated. The maximum-tolerated dose (MTD) has been reached and the Company is defining the recommended Phase 2 dose. Five patients have been on study for more than four months. Of these, four non-small cell lung cancer (NSCLC) patients have experienced stable disease for durations ranging from 8 to 13 months. One NSCLC patient achieved a confirmed partial response and other three patients all had tumor shrinkage accompanying their stable disease. Preclinical xenograft studies described in the poster indicate that combination of MGCD265 with docetaxel achieved greater antitumor responses than treatment with either agent alone. In patients, MGCD265 has been combined with a full dose of docetaxel (75mg/m2) and is well tolerated with no drug-drug interactions observed from preliminary pharmacokinetic evaluations. "
"
https://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=MYG.TO×tamp=20110405120200